Welcome

Clinical Genomics was formed in September 2006 to develop, extend, and commercialise molecular markers for colorectal disease. The enterprise includes experts in the science and business of colorectal cancer detection as well as institutional, commercial and clinical collaborative partners that understand this market. On top of a solid foundation of intellectual property protecting a panel of neoplasia biomarkers, CG has attracted significant financial and human resources to address this opportunity.

By applying advanced biotechnology and computational technologies to study the complex changes in gene expression that occur as normal colorectal cells become cancerous, we expect that an understanding of the molecular basis of the disease will enable us to provide products for improved diagnosis, management and possibly therapy of this disease.